Asciminib Roll-over Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent leczony asciminibem (samodzielnie lub z innymi lekami) w ramach badania Novartis, który według lekarza powinien kontynuować leczenie.
- •Pacjent stosował się do zasad poprzedniego badania i zgadza się przestrzegać zasad nowego badania (wizyty, leczenie, procedury).
✗ Disqualifies
- •Pacjent zakończył leczenie w poprzednim badaniu.
- •Pacjent ma poważne skutki uboczne związane z poprzednim leczeniem, które nie minęły.
- •Obecne leczenie pacjenta jest już refundowane w kraju.
- •Kobiety w ciąży lub karmiące piersią.
- •Kobiety w wieku rozrodczym, które nie stosują skutecznych metod antykoncepcji.
- •Mężczyźni w wieku rozrodczym przyjmujący niektóre leki (imatinib, nilotinib, bosutinib lub dasatinib), którzy nie chcą stosować antykoncepcji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 7 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (85)
Michigan Med University of Michigan
Ann Arbor, United States
Memorial Sloan Kettering
New York, United States
Oregon Health Sciences University
Portland, United States
Texas Oncology
Dallas, United States
Uni Of TX MD Anderson Cancer Cntr
Houston, United States
Medical College of Wisconsin
Milwaukee, United States
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Rio de Janeiro, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Chongqing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Zhengzhou, China
Novartis Investigative Site
Wuhan, China
Novartis Investigative Site
Changchun, China
Novartis Investigative Site
Xian, China
Novartis Investigative Site
Chengdu, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shenyang, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Ostrava, Czechia
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Frankfurt am Main, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Roma, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Kobe, Japan
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
George Town, Malaysia
Novartis Investigative Site
Johor Bahru, Malaysia
Novartis Investigative Site
Kuala Selangor, Malaysia
Novartis Investigative Site
Monterrey, Mexico
Novartis Investigative Site
Khoudh, Oman
Novartis Investigative Site
Katowice, Poland
Novartis Investigative Site
Krakow, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Wroclaw, Poland
Novartis Investigative Site
Lisbon, Portugal
Novartis Investigative Site
Porto, Portugal
Novartis Investigative Site
Timișoara, Romania
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Riyadh, Saudi Arabia
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Uijeongbu-si, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Jeollanam, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Santiago Compostela, Spain
Novartis Investigative Site
Badalona, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Spain
Novartis Investigative Site
Bilbao, Spain
Novartis Investigative Site
Santa Cruz, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Seville, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Taoyuan, Taiwan
Novartis Investigative Site
Samsun, Turkey (Türkiye)
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Oxford, United Kingdom
Novartis Investigative Site
Hanoi, Vietnam
Novartis Investigative Site
Ho Chi Minh City, Vietnam
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.